An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Varlitinib in Healthy Male Subjects
Latest Information Update: 17 Apr 2023
Price :
$35 *
At a glance
- Drugs Varlitinib (Primary)
- Indications Biliary cancer; Breast cancer; Cholangiocarcinoma; Gastric cancer; Liver cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors ASLAN Pharmaceuticals
- 08 Jan 2018 Status changed from recruiting to completed.
- 18 Dec 2017 New trial record